Movatterモバイル変換

[0]ホーム
URL:

DK0640619T4 - Erythropoietin analogs with additional glycosylation sites - Google Patents

Erythropoietin analogs with additional glycosylation sites

Info

Publication number
DK0640619T4
DK0640619T4DK94112732TDK94112732TDK0640619T4DK 0640619 T4DK0640619 T4DK 0640619T4DK 94112732 TDK94112732 TDK 94112732TDK 94112732 TDK94112732 TDK 94112732TDK 0640619 T4DK0640619 T4DK 0640619T4
Authority
DK
Denmark
Prior art keywords
glycosylation sites
additional glycosylation
erythropoietin analogs
hepo
analogue
Prior art date
Application number
DK94112732T
Other languages
Danish (da)
Other versions
DK0640619T3 (en
Inventor
Steven G Elliot
Thomas E Byrne
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=22319789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0640619(T4)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen IncfiledCriticalKirin Amgen Inc
Publication of DK0640619T3publicationCriticalpatent/DK0640619T3/en
Application grantedgrantedCritical
Publication of DK0640619T4publicationCriticalpatent/DK0640619T4/en

Links

Classifications

Landscapes

Abstract

The following are new: (1) an analogue of human erythropoietin (hEPO) comprising a sequence including \-1 additional glycosylation site; (2) an analogue of hEPO comprising a sequence with re-arrangement of \-1 glycosylation site; (3) a DNA sequence encoding the hEPOs of (1) and (2); and (4) a eukaryotic host cell transfected with the DNA of (3).
DK94112732T1993-08-171994-08-16 Erythropoietin analogs with additional glycosylation sitesDK0640619T4 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US10801693A1993-08-171993-08-17

Publications (2)

Publication NumberPublication Date
DK0640619T3 DK0640619T3 (en)1998-02-02
DK0640619T4true DK0640619T4 (en)2005-04-18

Family

ID=22319789

Family Applications (1)

Application NumberTitlePriority DateFiling Date
DK94112732TDK0640619T4 (en)1993-08-171994-08-16 Erythropoietin analogs with additional glycosylation sites

Country Status (27)

CountryLink
EP (1)EP0640619B2 (en)
JP (3)JP2938572B2 (en)
KR (2)KR100328769B1 (en)
CN (1)CN1057534C (en)
AT (1)ATE155796T1 (en)
AU (1)AU677097B2 (en)
CA (1)CA2147124C (en)
CZ (3)CZ291229B6 (en)
DE (2)DE10199059I2 (en)
DK (1)DK0640619T4 (en)
ES (1)ES2105442T5 (en)
FI (1)FI117136B (en)
GR (1)GR3024815T3 (en)
HK (1)HK1001589A1 (en)
HU (1)HU220334B (en)
IL (4)IL110669A (en)
LU (1)LU90850I2 (en)
LV (1)LV10972B (en)
NL (1)NL300075I2 (en)
NO (2)NO323104B1 (en)
NZ (1)NZ273134A (en)
RU (1)RU2159814C2 (en)
SI (1)SI0640619T2 (en)
SK (1)SK282003B6 (en)
UA (1)UA49793C2 (en)
WO (1)WO1995005465A1 (en)
ZA (1)ZA946122B (en)

Families Citing this family (245)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7217689B1 (en)1989-10-132007-05-15Amgen Inc.Glycosylation analogs of erythropoietin
FR2686899B1 (en)1992-01-311995-09-01Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5614184A (en)*1992-07-281997-03-25New England Deaconess HospitalRecombinant human erythropoietin mutants and therapeutic methods employing them
US5989538A (en)*1995-02-151999-11-23Amgen Inc.Mpl ligand analogs
US5696250A (en)*1995-02-151997-12-09Amgen Inc.DNA encoding megakaryocyte growth and development factor analogs
JPH11514232A (en)*1995-10-091999-12-07ファルマシア・アンド・アップジョン・カンパニー Acceptor polypeptide for N-acetylgalactosaminyltransferase
KR100400637B1 (en)*1996-02-062004-03-10씨제이 주식회사Biologically useful peptide
US6504007B1 (en)1996-03-142003-01-07Genentech, Inc.GDNF receptor
US5952226A (en)*1996-11-051999-09-14Modex TherapeutiquesHypoxia responsive EPO producing cells
DE69726571T2 (en)*1997-09-012004-11-04Aventis Pharma Deutschland Gmbh Recombinant human erythropoietin with an advantageous glycosylation pattern
CA2312188C (en)1997-12-082010-06-29Lexigen Pharmaceuticals Corp.Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
AU775422B2 (en)1998-06-152004-07-29Gtc Biotherapeutics, Inc.Erythropoietin analog-human serum albumin fusion
DK1123313T3 (en)*1998-10-232007-06-18Amgen Inc Methods and compositions for the prevention and treatment of anemia
US7304150B1 (en)1998-10-232007-12-04Amgen Inc.Methods and compositions for the prevention and treatment of anemia
DE19857609A1 (en)1998-12-142000-06-15Hannelore Ehrenreich Use of erythropoietin for the treatment of human cerebral ischemia
CA2359840C (en)*1999-02-122012-10-23Amgen Inc.Glycosylated leptin compositions and related methods
US7345019B1 (en)1999-04-132008-03-18The Kenneth S. Warren Institute, Inc.Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en)1999-04-132007-12-18The Kenneth S. Warren Institute, Inc.Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US8236561B2 (en)1999-04-152012-08-07Crucell Holland B.V.Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en)1999-04-152007-11-20Crucell Holland B.V.Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en)1999-04-152005-02-15Crucell Holland B.V.Recombinant protein production in a human cell
US7604960B2 (en)1999-04-152009-10-20Crucell Holland B.V.Transient protein expression methods
US6555343B1 (en)1999-05-072003-04-29Genentech Inc.Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6831060B2 (en)1999-05-072004-12-14Genentech, Inc.Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
JP3660880B2 (en)*1999-05-072005-06-15ジェネンテック・インコーポレーテッド Novel chimpanzee erythropoietin (CHEPO) polypeptide and nucleic acid encoding the same
RU2232163C2 (en)*1999-07-022004-07-10Ф.Хоффманн-Ля Рош АгConjugates of erythropoietin and polyethylene glycol, pharmaceutical compositions (variants), method for prophylactic and/or therapeutic treatment of disturbances and method for preparing conjugate or composition
JO2291B1 (en)1999-07-022005-09-12اف . هوفمان لاروش ايه جيErythopintin derivatives
CZ299516B6 (en)*1999-07-022008-08-20F. Hoffmann-La Roche AgErythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
US7067110B1 (en)1999-07-212006-06-27Emd Lexigen Research Center Corp.Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en)1999-07-212003-08-05Lexigen Pharm CorpFC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (en)1999-08-092011-10-12メルク パテント ゲーエムベーハー Complex cytokine-antibody complex
JP2003514552A (en)1999-11-122003-04-22メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Erythropoietin morphology with improved properties
US7192759B1 (en)1999-11-262007-03-20Crucell Holland B.V.Production of vaccines
US7521220B2 (en)1999-11-262009-04-21Crucell Holland B.V.Production of vaccines
US7527961B2 (en)1999-11-262009-05-05Crucell Holland B.V.Production of vaccines
DE60122286T2 (en)2000-02-112007-08-02Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
US6586398B1 (en)*2000-04-072003-07-01Amgen, Inc.Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2003530838A (en)2000-04-122003-10-21ヒューマン ゲノム サイエンシズ インコーポレイテッド Albumin fusion protein
DE60134003D1 (en)*2000-04-212008-06-26Amgen Inc METHOD AND COMPOSITIONS FOR AVOIDING AND TREATING ANEMIA
DE60109625T3 (en)*2000-05-152017-08-03F. Hoffmann-La Roche Ag LIQUID MEDICINE PREPARATION CONTAINING AN ERYTHROPOIETIN DERIVATIVE
US7259146B2 (en)2000-05-262007-08-21Ortho-Mcneil Pharmaceutical, Inc.Neuroprotective peptides
CZ2003214A3 (en)2000-06-292003-08-13Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated response by combined treatment with immunocytokine uptake enhancers
EP1336410A4 (en)2000-08-042005-10-12Chugai Pharmaceutical Co LtdProtein injection preparations
AU2001277781A1 (en)2000-08-112002-02-25Chugai Seiyaku Kabushiki KaishaStabilized antibody-containing preparations
AU2002222740A1 (en)*2000-12-112002-06-24Cheil Jedang CorporationFusion protein having the enhanced in vivo activity of erythropoietin
KR101229995B1 (en)*2000-12-112013-02-06씨제이 주식회사Fusion protein having the enhanced in vivo activity of erythropoietin
MXPA03005406A (en)2000-12-202003-09-25Hoffmann La RocheErythropoietin conjugates.
US6531121B2 (en)2000-12-292003-03-11The Kenneth S. Warren Institute, Inc.Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en)2000-12-292010-08-03The Kenneth S. Warren Institute, Inc.Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en)2000-12-292003-04-17Michael BrinesTissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (en)2000-12-292002-08-29Kenneth S Warren Inst Inc PROTECTION AND IMPROVEMENT OF CELLS, FABRICS AND ORGANS RESPONDING TO Erythropoietin
JP2005501801A (en)2001-02-022005-01-20オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Neurological dysfunction treatment comprising fructopyranose sulfamate and erythropoietin
JP4234438B2 (en)2001-03-072009-03-04メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Expression technology of protein containing hybrid isotype antibody part
JP4391086B2 (en)2001-03-092009-12-24中外製薬株式会社 Protein purification method
DE10112825A1 (en)2001-03-162002-10-02Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
WO2002079415A2 (en)2001-03-302002-10-10Lexigen Pharmaceuticals Corp.Reducing the immunogenicity of fusion proteins
FR2823220B1 (en)*2001-04-042003-12-12Genodyssee NOVEL ERYTHROPOIETIN (EPO) POLYNUCLEOTIDES AND POLYPEPTIDES
EP1382964A4 (en)2001-04-172009-06-10Chugai Pharmaceutical Co LtdMethod of quantifying surfactant
DK1383785T3 (en)2001-05-032011-05-23Merck Patent Gmbh Recombinant tumor-specific antibody and its use
US6930086B2 (en)*2001-09-252005-08-16Hoffmann-La Roche Inc.Diglycosylated erythropoietin
US7214660B2 (en)2001-10-102007-05-08Neose Technologies, Inc.Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en)2001-10-102007-02-06Neose Technologies, Inc.Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US6818613B2 (en)2001-11-072004-11-16Ortho-Mcneil Pharmaceutical, Inc.Aqueous sustained-release formulations of proteins
AU2002357019A1 (en)2001-11-282003-06-10Ortho-Mcneil Pharmaceutical, Inc.Erythropoietin dosing regimen for treating anemia
KR100467750B1 (en)*2001-11-292005-01-24씨제이 주식회사Fusion protein having the enhanced in vivo activity of erythropoietin
KR100467751B1 (en)*2001-12-032005-01-24씨제이 주식회사Fusion protein having the enhanced in vivo erythropoietin activity
MXPA04005266A (en)2001-12-042004-10-11Merck Patent GmbhImmunocytokines with modulated selectivity.
PT1465987E (en)2001-12-072008-04-15Crucell Holland BvProduction of viruses, viral isolates and vaccines
ES2425738T3 (en)2001-12-212013-10-17Human Genome Sciences, Inc. Albumin Fusion Proteins
DE10209821A1 (en)2002-03-062003-09-25Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10209822A1 (en)2002-03-062003-09-25Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
WO2003078959A2 (en)2002-03-112003-09-25Ortho Mcneil Pharmaceutical, IncMethods for shp1 mediated neuroprotection
US20030191056A1 (en)2002-04-042003-10-09Kenneth WalkerUse of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040122216A1 (en)*2002-07-012004-06-24Jacob NielsenRecombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
AU2003246486A1 (en)*2002-07-192004-02-09Cangene CorporationPegylated erythropoietic compounds
DE10234192B4 (en)2002-07-262009-11-26Epoplus Gmbh Co.Kg Use of erythropoietin
EP1541165A4 (en)2002-08-272009-06-24Chugai Pharmaceutical Co LtdMethod of stabilizing protein solution preparation
US7459435B2 (en)2002-08-292008-12-02Hoffmann-La Roche Inc.Treatment of disturbances of iron distribution
WO2004022593A2 (en)*2002-09-092004-03-18Nautilus BiotechRational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP1681303B1 (en)2002-09-112013-09-04Fresenius Kabi Deutschland GmbHHASylated polypeptides, especially HASylated erythropoietin
WO2004024761A1 (en)2002-09-112004-03-25Fresenius Kabi Deutschland GmbhHasylated polypeptides, especially hasylated erythropoietin
DE20321793U1 (en)2002-09-112010-06-02Fresenius Kabi Deutschland Gmbh Hydroxyalkyl starch derivatives
HUE027134T2 (en)2002-09-112016-10-28Chugai Pharmaceutical Co LtdMethod of purifying protein
ES2314238T3 (en)2002-10-082009-03-16Fresenius Kabi Deutschland Gmbh CONJUGATES OF PHARMACEUTICALLY ACTIVE OLIGOSACARIDS.
CN1726284A (en)*2002-10-172006-01-25法明知识产权股份有限公司Protein modification
US7459436B2 (en)2002-11-222008-12-02Hoffmann-La Roche Inc.Treatment of disturbances of iron distribution
RU2366664C2 (en)2002-12-172009-09-10Мерк Патент ГмбхHumanised antibody (h14,18) based on mouse antibody 14,18, contacting gd2, and its fusion with il-2
EP1594530A4 (en)2003-01-222006-10-11Human Genome Sciences IncAlbumin fusion proteins
EP2338333B1 (en)2003-04-092017-09-06ratiopharm GmbHGlycopegylation methods and proteins/peptides produced by the methods
CN101328473B (en)2003-05-092012-05-02克鲁塞尔荷兰公司Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
US9005625B2 (en)2003-07-252015-04-14Novo Nordisk A/SAntibody toxin conjugates
KR100632985B1 (en)*2003-07-262006-10-11메덱스젠 주식회사 Methods for Enhancing the Potency of Bioactive Regulatory Proteins and Exemplary Variants
WO2005014655A2 (en)2003-08-082005-02-17Fresenius Kabi Deutschland GmbhConjugates of hydroxyalkyl starch and a protein
JP2007517769A (en)2003-09-292007-07-05ウォーレン ファーマシューティカルズ，インコーポレーテッド Tissue protective cytokines for the treatment and prevention of sepsis and adhesion formation
US20080305992A1 (en)2003-11-242008-12-11Neose Technologies, Inc.Glycopegylated erythropoietin
PL1699915T3 (en)2003-12-302010-11-30Augustinus BaderUse of erythropoietin for liver tissue regeneration
BRPI0417916A (en)2003-12-312007-04-10Merck Patent Gmbh fc-erythropoietin fusion protein with improved pharmacokinetics
DE102004004509B4 (en)2004-01-232010-07-01Epoplus Gmbh Co.Kg Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
AR048035A1 (en)2004-03-112006-03-22Fresenius Kabi De Gmbh CONJUGADOS DE ALMIDON DE HIDROXIALQUILO AND A PROTEIN, PREPARED BY REDUCING AMINATION
WO2006010143A2 (en)2004-07-132006-01-26Neose Technologies, Inc.Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US7597884B2 (en)2004-08-092009-10-06Alios Biopharma, Inc.Hyperglycosylated polypeptide variants and methods of use
EP3061461A1 (en)2004-10-292016-08-31ratiopharm GmbHRemodeling and glycopegylation of fibroblast growth factor (fgf)
MX2007008229A (en)2005-01-102007-09-11Neose Technologies IncGlycopegylated granulocyte colony stimulating factor.
US9187546B2 (en)2005-04-082015-11-17Novo Nordisk A/SCompositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9988427B2 (en)2005-05-132018-06-05Charite Universitaetsmedizen-BerlinErythropoietin variants
EP1736481A1 (en)2005-05-132006-12-27Charite Universitätsmedizin-BerlinErythropoietin variants
US20070105755A1 (en)2005-10-262007-05-10Neose Technologies, Inc.One pot desialylation and glycopegylation of therapeutic peptides
CN100432107C (en)*2005-10-252008-11-12北京大学Protein for promoting erythrocyte growth factor activity and its use
US20090048440A1 (en)2005-11-032009-02-19Neose Technologies, Inc.Nucleotide Sugar Purification Using Membranes
AU2006322028C1 (en)2005-12-082025-09-04Amgen Inc.Improved host cells and culture methods
US7972810B2 (en)2005-12-082011-07-05Amgen Inc.Production of glycoproteins using manganese
DE102006004008A1 (en)2006-01-272007-08-02Hannelore Prof. Dr. Dr. EhrenreichTreating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
WO2007108505A1 (en)2006-03-222007-09-27Chugai Seiyaku Kabushiki KaishaErythropoietin solution preparation
CN101062407A (en)2006-04-292007-10-31中国科学院上海生命科学研究院Function of erythropoietin in the preventing and treating of retinal injury
WO2007136752A2 (en)2006-05-192007-11-29Glycofi, Inc.Erythropoietin compositions
MX2009000685A (en)2006-07-212009-01-30Amgen IncMethod of detecting and/ or measuring hepcidin in a sample.
WO2008011633A2 (en)2006-07-212008-01-24Neose Technologies, Inc.Glycosylation of peptides via o-linked glycosylation sequences
US20100234278A1 (en)2006-08-222010-09-16Makoto SugawaProphylactic and/or therapeutic agents for peripheral neuropathy
EP2054521A4 (en)2006-10-032012-12-19Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
CN101337988B (en)*2006-10-312013-01-09沈阳三生制药有限责任公司 A new analogue of erythropoietin
US8895303B2 (en)2006-11-132014-11-25Charite-Universitatsmedizin BerlinMethod of cell culture and method of treatment comprising a vEPO protein variant
EP2120998B1 (en)2006-11-282013-08-07HanAll Biopharma Co., Ltd.Modified erythropoietin polypeptides and uses thereof for treatment
AR065613A1 (en)2007-03-092009-06-17Chugai Pharmaceutical Co Ltd PROTECTION AGENTS FOR TRANSPLANTED ORGANS
PL2144923T3 (en)2007-04-032013-12-31Biogenerix AgMethods of treatment using glycopegylated g-csf
CN101778859B (en)2007-06-122014-03-26诺和诺德公司Improved process for the production of nucleotide sugars
AU2008261212A1 (en)*2007-06-152008-12-18University Of ZurichTreatment for Alzheimer' s disease
RU2335296C1 (en)*2007-06-262008-10-10Сергей Марович ДудкинPharmaceutical composition for prevention and treatment of neurologic diseases
CN103073631A (en)*2007-07-022013-05-01沈阳三生制药有限责任公司Hemopoietin analogue
CN103113464B (en)*2007-07-022014-08-20沈阳三生制药有限责任公司Natural human erythropoietin analogue
WO2009010107A1 (en)2007-07-192009-01-22Hannelore EhrenreichUse of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
AU2008304111B2 (en)2007-09-272014-04-24Amgen Inc.Pharmaceutical formulations
EP2219602A1 (en)2007-11-152010-08-25Amgen, IncAqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
EP2070950A1 (en)2007-12-142009-06-17Fresenius Kabi Deutschland GmbHHydroxyalkyl starch derivatives and process for their preparation
EP2247618B1 (en)2008-01-252014-06-11Amgen, IncFerroportin antibodies and methods of use
US9938333B2 (en)2008-02-082018-04-10Ambrx, Inc.Modified leptin polypeptides and their uses
EP2095829A1 (en)2008-02-272009-09-02LEK Pharmaceuticals D.D.Selenium containing modifying agents and conjugates
CA2715465C (en)2008-02-272017-03-21Novo Nordisk A/SConjugated factor viii molecules
CN102105582A (en)2008-04-212011-06-22诺沃-诺迪斯克有限公司Hyperglycosylated human coagulation factor IX
EP2620448A1 (en)2008-05-012013-07-31Amgen Inc.Anti-hepcidin antibodies and methods of use
CN102164954B (en)2008-09-232018-04-06弗·哈夫曼-拉罗切有限公司The purifying of hematopoietin
NZ592250A (en)2008-09-262012-11-30Lilly Co EliModified animal erythropoietin polypeptides and their uses
EP3693014A1 (en)2008-11-132020-08-12The General Hospital CorporationMethods and compositions for regulating iron homeostasis by modulation bmp-6
KR101666144B1 (en)*2009-02-192016-10-13셀리아 파마슈티칼즈 에이피에스Process for purifying lipopeptides
US20100272816A1 (en)2009-04-272010-10-28Wolfgang RudingerMicrocapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
WO2011011674A2 (en)2009-07-242011-01-27Dr. Reddy's Laboratories Ltd.Production of erythropoiesis stimulating protein using metal ions
WO2011024025A1 (en)*2009-08-282011-03-03Avesthagen LimitedAn erythropoietin analogue and a method thereof
US9662271B2 (en)2009-10-232017-05-30Amgen Inc.Vial adapter and system
SG194370A1 (en)2010-06-072013-11-29Amgen IncDrug delivery device
US8193296B2 (en)2010-06-302012-06-05Nike, Inc.Golf balls including crosslinked thermoplastic polyurethane
US20120115637A1 (en)2010-06-302012-05-10Nike, Inc.Golf Balls Including A Crosslinked Thermoplastic Polyurethane Cover Layer Having Improved Scuff Resistance
RU2451071C1 (en)*2010-12-102012-05-20Российская Федерация, от имени которой выступает Министерство образования и науки Российской Федерации (Минобрнауки России)Mus musculus cultivated hybrid cell strain producer of monoclonal antibodies specific to human recombinant erythropoietin (versions)
CA2831100C (en)2011-03-312020-02-18Mark Dominis HoltVial adapter and system
PL2699293T3 (en)2011-04-202019-08-30Amgen Inc.Autoinjector apparatus
US8979676B2 (en)2011-08-232015-03-17Nike, Inc.Multi-core golf ball having increased initial velocity at high swing speeds relative to low swing speeds
US9089739B2 (en)2011-08-232015-07-28Nike, Inc.Multi-core golf ball having increased initial velocity
DK3045187T3 (en)2011-10-142019-06-11Amgen Inc INJECTOR AND COLLECTION PROCEDURE
KR101443257B1 (en)*2011-10-182014-09-19주식회사 종근당Methods for Purifying Erythropoietin Analogs Having Lower Isoelectric Point
CN102788720B (en)*2012-06-052016-01-06西北大学A kind of filter membrane auxiliary separating connects sugar chain and discrimination method thereof from the full N-of glycoprotein in biological specimen
CA3206182A1 (en)2012-11-212014-05-30Amgen Inc.Drug delivery device including insertion member and reservoir
CN103864913A (en)*2012-12-182014-06-18联亚生技开发股份有限公司Recombinant proteins
CA2904661C (en)2013-03-152022-03-15Amgen Inc.Drug cassette, autoinjector, and autoinjector system
ES2695166T3 (en)2013-03-152019-01-02Intrinsic Lifesciences Llc Antihepcidin antibodies and uses thereof
ES2973257T3 (en)2013-03-152024-06-19Amgen Inc Drug cassette, autoinjector and autoinjector system
BR112015022042B1 (en)2013-03-152023-01-10Amgen Inc INJECTOR FOR INJECTING A THERAPEUTIC PRODUCT
SG11201507878SA (en)2013-03-222015-10-29Amgen IncInjector and method of assembly
JP7051293B2 (en)2013-10-242022-04-11アムジエン・インコーポレーテツド Drug delivery system with temperature sensing control
BR112016008946B1 (en)2013-10-242022-12-27Amgen Inc INJECTORS AND METHOD FOR ASSEMBLING THE INJECTORS
KR101414897B1 (en)2013-11-292014-07-04씨제이헬스케어 주식회사A method for purifying darbepoetin alfa
WO2015119906A1 (en)2014-02-052015-08-13Amgen Inc.Drug delivery system with electromagnetic field generator
MX388536B (en)2014-05-072025-03-20Amgen Inc AUTO-INJECTOR WITH SHOCK-REDUCING ELEMENTS.
CN106470717B (en)2014-06-032020-09-11安姆根有限公司 Drug delivery system and method of use
US10287336B2 (en)2014-09-182019-05-14AskGene Pharma, Inc.Feline erythropoietin receptor agonists
EP3197915A4 (en)2014-09-222018-12-19Intrinsic Lifesciences LLCHumanized anti-hepcidin antibodies and uses thereof
MX2021014323A (en)2014-10-142023-02-02Amgen IncDrug injection device with visual and audio indicators.
JP6716566B2 (en)2014-12-192020-07-01アムジエン・インコーポレーテツド Drug delivery device with proximity sensor
US11357916B2 (en)2014-12-192022-06-14Amgen Inc.Drug delivery device with live button or user interface field
CA2976935C (en)2015-02-172020-03-10Amgen Inc.Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en)2015-02-272022-04-13Amgen, IncDrug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en)2015-09-022017-03-09Amgen Inc.Syringe assembly adapter for a syringe
JP7082568B2 (en)2015-12-092022-06-08アムジエン・インコーポレーテツド Automatic syringe with signal transduction cap
US11154661B2 (en)2016-01-062021-10-26Amgen Inc.Auto-injector with signaling electronics
US10604779B2 (en)2016-03-092020-03-31Jcr Pharmaceuticals Co., Ltd.Method for production of mutant-type human erythropoietin
EP4035711B1 (en)2016-03-152025-06-04Amgen Inc.Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en)2016-04-292017-11-02Amgen Inc.Drug delivery device with messaging label
US11389588B2 (en)2016-05-022022-07-19Amgen Inc.Syringe adapter and guide for filling an on-body injector
MX2018013616A (en)2016-05-132019-02-21Amgen IncVial sleeve assembly.
EP3458988B1 (en)2016-05-162023-10-18Amgen Inc.Data encryption in medical devices with limited computational capability
GB2550418A (en)2016-05-202017-11-22Laing PeterAn improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
WO2017209899A1 (en)2016-06-032017-12-07Amgen Inc.Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en)2016-07-012018-01-04Amgen Inc.Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en)2016-08-172019-10-31Amgen Inc.Drug delivery device with placement detection
EP3532127A1 (en)2016-10-252019-09-04Amgen Inc.On-body injector
JP2020503976A (en)2017-01-172020-02-06アムジエン・インコーポレーテツド Injection device and associated methods of use and assembly
AU2018220538B2 (en)2017-02-172023-12-14Amgen Inc.Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018221351B2 (en)2017-02-172023-02-23Amgen Inc.Insertion mechanism for drug delivery device
JP6258536B1 (en)2017-03-032018-01-10協和発酵キリン株式会社 Method for producing darbepoetin composition and method for culturing darbepoetin-producing cells
JP2020508803A (en)2017-03-062020-03-26アムジエン・インコーポレーテツド Drug delivery device with anti-actuation feature
SG11201908058UA (en)2017-03-072019-09-27Amgen IncNeedle insertion by overpressure
IL268386B2 (en)2017-03-092023-11-01Amgen Inc Insertion mechanism for a drug delivery device
EP3570871B1 (en)2017-03-202020-11-18H. Hoffnabb-La Roche AgMethod for in vitro glycoengineering of an erythropoiesis stimulating protein
CN114588404B (en)2017-03-282024-07-09美国安进公司Plunger rod and syringe assembly system and method
CA3065540A1 (en)2017-06-062018-12-13Kindred Biosciences, Inc.Erythropoietin and analogs for veterinary use
EP3634539A1 (en)2017-06-082020-04-15Amgen Inc.Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (en)2017-06-082023-01-06アムジエン・インコーポレーテツド Torque driven drug delivery device
MX2019015472A (en)2017-06-222020-02-19Amgen IncDevice activation impact/shock reduction.
CA3063921A1 (en)2017-06-232018-12-27Amgen Inc.Electronic drug delivery device comprising a cap activated by a switch assembly
ES2972207T3 (en)2017-07-142024-06-11Amgen Inc Needle insertion-retraction system with double torsion spring system
MA49626A (en)2017-07-212020-05-27Amgen Inc GAS PERMEABLE SEALING ELEMENT FOR DRUG CONTAINER AND ASSEMBLY PROCEDURES
MA49677A (en)2017-07-252021-04-21Amgen Inc DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS
MA49676A (en)2017-07-252020-06-03Amgen Inc DRUG ADMINISTRATION DEVICE EQUIPPED WITH A CONTAINER ACCESS SYSTEM AND ASSOCIATED ASSEMBLY PROCEDURE
MA49838A (en)2017-08-092020-06-17Amgen Inc DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
MA49897A (en)2017-08-182020-06-24Amgen Inc ON-BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en)2017-08-222021-08-31Amgen Inc.Needle insertion mechanism for drug delivery device
EP3691717B1 (en)2017-10-042023-02-08Amgen Inc.Flow adapter for drug delivery device
US11813426B2 (en)2017-10-062023-11-14Amgen Inc.Drug delivery device including seal member for needle of syringe
MA50348A (en)2017-10-092020-08-19Amgen Inc DRUG ADMINISTRATION DEVICE INCLUDING A TRAINING ASSEMBLY AND ASSOCIATED ASSEMBLY PROCEDURE
WO2019090086A1 (en)2017-11-032019-05-09Amgen Inc.Systems and approaches for sterilizing a drug delivery device
CA3079197A1 (en)2017-11-062019-05-09Amgen Inc.Drug delivery device with placement and flow sensing
US12053618B2 (en)2017-11-062024-08-06Amgen Inc.Fill-finish assemblies and related methods
MX2020004736A (en)2017-11-102020-08-13Amgen IncPlungers for drug delivery devices.
EP3710090A1 (en)2017-11-162020-09-23Amgen Inc.Door latch mechanism for drug delivery device
CN111263651B (en)2017-11-162022-06-17安进公司Auto-injector with pause and end point detection
US10835685B2 (en)2018-05-302020-11-17Amgen Inc.Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)2018-06-012021-08-10Amgen Inc.Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en)2018-07-242020-01-30Amgen Inc.Hybrid drug delivery devices with grip portion
WO2020023220A1 (en)2018-07-242020-01-30Amgen Inc.Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MA53375A (en)2018-07-242021-06-02Amgen Inc ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES
MA53379A (en)2018-07-242021-06-02Amgen Inc ADMINISTRATION DEVICES FOR THE ADMINISTRATION OF MEDICINES
MA53320A (en)2018-07-312021-11-03Amgen Inc FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE
CA3106452A1 (en)2018-09-242020-04-02Amgen Inc.Interventional dosing systems and methods
AR113091A1 (en)2018-09-272020-01-22Univ Nacional Del Litoral MODIFIED HUMAN ERYTHROPOYETIN
AU2019350660B2 (en)2018-09-282024-09-26Amgen Inc.Muscle wire escapement activation assembly for a drug delivery device
MX2021003492A (en)2018-10-022021-06-18Amgen Inc INJECTION SYSTEMS FOR THE ADMINISTRATION OF DRUGS WITH TRANSMISSION OF INTERNAL FORCE.
CA3112214A1 (en)2018-10-052020-04-09Amgen Inc.Drug delivery device having dose indicator
KR20250127186A (en)2018-10-152025-08-26암젠 인크Drug delivery device having damping mechanism
SG11202101824VA (en)2018-10-152021-03-30Amgen IncPlatform assembly process for drug delivery device
TWI831847B (en)2018-11-012024-02-11美商安進公司Drug delivery devices with partial needle retraction and methods for operating the same
MA54048A (en)2018-11-012022-02-09Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
IL281908B2 (en)2018-11-012025-06-01Amgen Inc Drug delivery devices with partial drug delivery unit withdrawal
CA3137360A1 (en)2019-04-242020-10-29Amgen Inc.Syringe sterilization verification assemblies and methods
US20220273887A1 (en)2019-08-232022-09-01Amgen Inc.Drug delivery device with configurable needle shield engagement components and related methods
WO2022159414A1 (en)2021-01-222022-07-28University Of RochesterErythropoietin for gastroinfestinal dysfunction
IL307418A (en)2021-05-212023-12-01Amgen IncMethod of optimizing a filling recipe for a drug container
WO2023209074A1 (en)2022-04-282023-11-02Institut National de la Santé et de la Recherche MédicaleMethods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en)2022-11-022024-05-10F. Hoffmann-La Roche AgMethod for producing glycoprotein compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NZ210501A (en)*1983-12-131991-08-27Kirin Amgen IncErythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4954437A (en)*1986-09-151990-09-04Integrated Genetics, Inc.Cell encoding recombinant human erythropoietin
WO1991005867A1 (en)*1989-10-131991-05-02Amgen Inc.Erythropoietin isoforms

Also Published As

Publication numberPublication date
DE10199059I2 (en)2007-11-08
FI951792A0 (en)1995-04-13
NZ273134A (en)1997-11-24
UA49793C2 (en)2002-10-15
DK0640619T3 (en)1998-02-02
GR3024815T3 (en)1998-01-30
JP2938572B2 (en)1999-08-23
IL110669A (en)2008-11-26
CA2147124A1 (en)1995-02-23
JPH11155584A (en)1999-06-15
KR100328769B1 (en)2002-08-08
RU95115239A (en)1997-03-27
HU9501435D0 (en)1995-06-28
CZ291342B6 (en)2003-02-12
CZ91795A3 (en)1996-03-13
NO323104B1 (en)2007-01-02
ZA946122B (en)1995-03-20
DE69404401D1 (en)1997-09-04
WO1995005465A1 (en)1995-02-23
DE10199059I1 (en)2002-02-07
DE69404401T2 (en)1998-02-19
IL136188A0 (en)2001-07-24
NL300075I2 (en)2002-04-02
HUT72849A (en)1996-05-28
JP2004331671A (en)2004-11-25
AU7632794A (en)1995-03-14
EP0640619B2 (en)2005-03-23
CA2147124C (en)2002-11-05
CZ291229B6 (en)2003-01-15
NO951445D0 (en)1995-04-12
LU90850I2 (en)2002-01-07
AU677097B2 (en)1997-04-10
EP0640619B1 (en)1997-07-23
JPH08506023A (en)1996-07-02
SK50295A3 (en)1995-08-09
IL192290A0 (en)2008-12-29
ES2105442T5 (en)2005-07-16
LV10972B (en)1996-10-20
LV10972A (en)1995-12-20
SI0640619T1 (en)1998-02-28
FI117136B (en)2006-06-30
HU220334B (en)2001-12-28
FI951792L (en)1995-05-18
SK282003B6 (en)2001-10-08
RU2159814C2 (en)2000-11-27
CN1057534C (en)2000-10-18
IL136189A0 (en)2001-07-24
CN1105030A (en)1995-07-12
HK1001589A1 (en)1998-06-26
DE69404401T3 (en)2005-11-24
JP3664590B2 (en)2005-06-29
ES2105442T3 (en)1997-10-16
NL300075I1 (en)2002-03-01
JP3664723B2 (en)2005-06-29
IL110669A0 (en)1994-11-11
ATE155796T1 (en)1997-08-15
NO2007008I2 (en)2011-02-21
EP0640619A1 (en)1995-03-01
NO951445L (en)1995-06-16
CZ291343B6 (en)2003-02-12
NO2007008I1 (en)2007-07-23
SI0640619T2 (en)2005-06-30
KR960701994A (en)1996-03-28

Similar Documents

PublicationPublication DateTitle
DK0640619T4 (en) Erythropoietin analogs with additional glycosylation sites
DE58905705D1 (en) BONE SCREW.
DE3885731D1 (en) Bone screw.
DE59400258D1 (en) Bone screw
FI864372A0 (en) DISPLAY CONTROL OF FOER HISSAR.
KR910006808A (en) Feedback control system
DE69325877D1 (en) Processor control code update
DE59205477D1 (en) Stabilizer mixture
DK494589D0 (en) SUBSTITUTED 1,3,5-TRIAZINTRIONS AND THEIR USE AND INTERMEDIATES FOR THEIR PREPARATION
DE69030439D1 (en) FINGER-CONTROLLABLE CONTROL UNITS
KR950700316A (en) RECOMBINANT GIBBERELLIN DNA AND USES THEREOF
DE59302226D1 (en) High voltage control panel
FI904064A0 (en) Adjustable frequency control for percussion
AT399706B (en) BARREL
FI942623L (en) Recombinant viruses containing an artificial proteolytic cleavage site
DK355289D0 (en) 2,2-DIHALOGENCYCLOPROPYL-HYDROXY-ETHYLTRIAZOLES, PROCEDURES AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE
ATA208789A (en) CONTROL BAR
FI893942A7 (en) Factor regulating gene expression
KR910009665U (en) Timetable with time control
KR910010219U (en) Facsimile control panel switchgear
ITVR970024U4 (en) CONTROL KNOB
IT8404785V0 (en) PERFECTED MEMBRANE KEYBOARD AND PERFECTED SWITCH FOR THE REALIZATION OF THE KEYBOARD
DK126890D0 (en) BONE CEMENT
[8]ページ先頭
©2009-2025 Movatter.jp